肠道微生物群-胰岛素耐药性研究的全球趋势和协作网络:全面的文献计量分析 (2000-2024)
Gulshara Zh Abildinova1, Valeriy V Benberin1,2, Tamara A Vochshenkova1
1Gerontology Center, Medical Center Hospital of the President's Affairs Administration of the Republic of Kazakhstan, Astana, Kazakhstan.
Frontiers in medicine
|August 30, 2024
概括
全球对肠道微生物群和胰岛素耐药性的研究正在迅速扩大. 这个领域突出了肠道微生物群在代谢健康和潜在的治疗应用中的关键作用.
科学领域:
- 代谢健康 代谢健康
- 微生物组研究 微生物组研究
- 图书统计学 图书统计学
背景情况:
- 人的肠道微生物群是代谢健康的组成部分.
- 肠道微生物群的组成与胰岛素耐药性密切相关.
- 了解这种关系是代谢障碍研究的关键.
研究的目的:
- 分析全球关于肠道微生物群和胰岛素耐药性的学术成果 (2000-2024年).
- 确定这一领域的趋势,关键贡献者和研究热点.
主要方法:
- 对Scopus和Web of Science核心数据库的图书统计分析.
- 搜索术语:标题/摘要中的"胃肠道微生物组"和"胰岛素抵抗".
- 分析了来自510个来源的1884项研究.
主要成果:
- 显著的年增长率 (22.08%) 和高的平均引用率 (51.36).
- 关键的机制涉及短链脂肪酸 (SCFA) 和肠道激素在葡萄糖代谢和炎症.
- "食品和功能"杂志的作者纽夫多普·M.被确定为高生产力.
结论:
- 越来越多的出版物表明,人们越来越认识到肠道微生物群对胰岛素抵抗的治疗潜力.
- 未来的研究需要标准化的方法和大规模的临床试验.
- 这个领域对代谢障碍的新疗法充满希望.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Glucose Absorption Into the Small Intestine
31.5K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.5K


